共 158 条
[1]
Abdi J.(2013)Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms Oncotarget 4 2186-2207
[2]
Chen G.(2004)The proteasome: a suitable antineoplastic target Nat. Rev. Cancer 4 349-360
[3]
Chang H.(2009)Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann. N.Y. Acad. Sci 1171 59-76
[4]
Adams J.(2017)Cell cycle regulation and anticancer drug discovery Cancer Biol. Med. 14 348-362
[5]
Aggarwal B.B.(2013)Control of cell cycle transcription during G1 and S phases Nat. Rev., Mol. Cell Biol 14 518-528
[6]
Kunnumakkara A.B.(2005)Overexpression of Cyclin D1 promotes tumor cell growth and confers resistance to Cisplatin-mediated apoptosis in an Elastase-myc transgene– expressing pancreatic tumor cell line Clin. Cancer Res 11 6075-6086
[7]
Harikumar K.B.(2005)Bortezomib: a valuable new antineoplastic strategy in multiple myeloma Acta Oncol 44 440-448
[8]
Gupta S.R.(2010)Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer Cell Division 5 1-13
[9]
Tharakan S.T.(2021)Genetic abnormalities in multiple myeloma: prognostic and therapeutic ımplications Cells 10 336-253
[10]
Koca C.(2011)Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives Curr. Cancer Drug Targets 11 239-51